dc.contributor.author	O'Donnell, Charlotte
dc.contributor.author	Mahmoud, Amr
dc.contributor.author	Keane, Jonathan
dc.contributor.author	Murphy, Carola T.
dc.contributor.author	White, Declan
dc.contributor.author	Carey, Sinead
dc.contributor.author	O'Riordain, Micheal G.
dc.contributor.author	Bennett, Michael W.
dc.contributor.author	Brint, Elizabeth K.
dc.contributor.author	Houston, Aileen M.
dc.contributor.funder	Health Research Board	en
dc.contributor.funder	Pathological Society of Great Britain and Ireland	en
dc.date.accessioned	2019-09-05T08:49:56Z
dc.date.available	2019-09-05T08:49:56Z
dc.date.issued	2015-12-17
dc.date.updated	2019-09-02T06:06:15Z
dc.description.abstract	Background: Despite the importance of inflammation in cancer, the role of the cytokine IL-33, and its receptor ST2, in colon cancer is unclear. The aim of this study was to investigate the role of IL-33, and its receptor isoforms (ST2 and ST2L), in colon cancer. Methods: Serum levels of IL-33 and sST2 were determined with ELISA. ST2 and IL-33 expression was detected with quantitative real-time PCR (qRT–PCR), western blotting and immunohistochemistry. ST2 expression in CT26 cells was stably suppressed using ST2-specific shRNA. Cytokine and chemokine gene expression was detected with qRT–PCR. Results: Human colon tumours showed lower expression of ST2L as compared with adjacent non-tumour tissue (P<0.01). Moreover, the higher the tumour grade, the lower the expression of ST2L (P=0.026). Colon cancer cells expressed ST2 and IL-33 in vitro. Functional analyses showed that stimulation of tumour cells with IL-33 induced the expression of chemokine (C–C motif) ligand 2 (CCL2). Knockdown of ST2 in murine colon cancer cells resulted in enhanced tumour growth (P<0.05) in BALB/c mice in vivo. This was associated with a decrease in macrophage infiltration, with IL-33-induced macrophage recruitment reduced by antagonising CCL2 in vitro. Conclusion: The IL-33/ST2 signalling axis may have a protective role in colon carcinogenesis.	en
dc.description.sponsorship	Health Research Board of Ireland (PhD/2007/4); Pathological Society of Great Britain and Ireland (SGS 2014/10/04)	en
dc.description.status	Peer reviewed	en
dc.description.version	Published Version	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	O'Donnell, C., Mahmoud, A., Keane, J., Murphy, C., White, D., Carey, S., O'Riordain, M., Bennett, M. W., Brint, E. and Houston, A. (2015) 'An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer', British Journal Of Cancer, 114, pp. 37-43. doi: 10.1038/bjc.2015.433	en
dc.identifier.doi	10.1038/bjc.2015.433	en
dc.identifier.endpage	43	en
dc.identifier.issn	0007-0920
dc.identifier.journaltitle	British Journal of Cancer	en
dc.identifier.startpage	37	en
dc.identifier.uri	https://hdl.handle.net/10468/8457
dc.identifier.volume	114	en
dc.language.iso	en	en
dc.publisher	Nature Publishing Group	en
dc.relation.uri	https://www.nature.com/articles/bjc2015433
dc.rights	© 2016 Cancer Research UK. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/	en
dc.subject	Colon cancer	en
dc.subject	Inflammation	en
dc.subject	IL-33 ST2	en
dc.subject	CD8(+) T-Cells	en
dc.subject	Hepatocellular-carcinoma	en
dc.subject	Colorectal cancer	en
dc.subject	Prognostic factor	en
dc.subject	Interleukin-33	en
dc.subject	Expression	en
dc.subject	Serum	en
dc.subject	Metastasis	en
dc.subject	Effector	en
dc.subject	Colitis	en
dc.title	An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer	en
dc.type	Article (peer-reviewed)	en

An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer

Files

Original bundle

License bundle

Collections